The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

GS-4071     (3R,4R,5S)-4-acetamido-5- amino-3-pentan-3...

Synonyms: CHEMBL674, SureCN182903, AG-E-36281, CHEBI:73139, CS-0553, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Oseltamivir acid


High impact information on Oseltamivir acid


Chemical compound and disease context of Oseltamivir acid


Biological context of Oseltamivir acid


Anatomical context of Oseltamivir acid


Associations of Oseltamivir acid with other chemical compounds


Gene context of Oseltamivir acid


Analytical, diagnostic and therapeutic context of Oseltamivir acid

  • Oseltamivir is rapidly hydrolyzed by hepatic carboxylesterases to Ro 64-0802, which is then exclusively excreted by glomerular filtration and active tubular secretion without further metabolism [16].
  • CONCLUSIONS: A 30 mg dose of oseltamivir given once weekly in CAPD or after alternate sessions in HD patients provides sufficient exposure to oseltamivir carboxylate to allow safe and effective anti-influenza treatment and prophylaxis [20].
  • A precolumn fluorescence derivatization HPLC method is described for the analysis of GS4071 in rat plasma [21].


  1. Oral oseltamivir in human experimental influenza B infection. Hayden, F.G., Jennings, L., Robson, R., Schiff, G., Jackson, H., Rana, B., McClelland, G., Ipe, D., Roberts, N., Ward, P. Antivir. Ther. (Lond.) (2000) [Pubmed]
  2. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. Molla, A., Kati, W., Carrick, R., Steffy, K., Shi, Y., Montgomery, D., Gusick, N., Stoll, V.S., Stewart, K.D., Ng, T.I., Maring, C., Kempf, D.J., Kohlbrenner, W. J. Virol. (2002) [Pubmed]
  3. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. Matrosovich, M.N., Matrosovich, T.Y., Gray, T., Roberts, N.A., Klenk, H.D. J. Virol. (2004) [Pubmed]
  4. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Tai, C.Y., Escarpe, P.A., Sidwell, R.W., Williams, M.A., Lew, W., Wu, H., Kim, C.U., Mendel, D.B. Antimicrob. Agents Chemother. (1998) [Pubmed]
  5. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Gubareva, L.V., Webster, R.G., Hayden, F.G. Antimicrob. Agents Chemother. (2001) [Pubmed]
  6. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. Matrosovich, M., Matrosovich, T., Carr, J., Roberts, N.A., Klenk, H.D. J. Virol. (2003) [Pubmed]
  7. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. McKimm-Breschkin, J.L., Sahasrabudhe, A., Blick, T.J., McDonald, M., Colman, P.M., Hart, G.J., Bethell, R.C., Varghese, J.N. J. Virol. (1998) [Pubmed]
  8. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Kati, W.M., Montgomery, D., Carrick, R., Gubareva, L., Maring, C., McDaniel, K., Steffy, K., Molla, A., Hayden, F., Kempf, D., Kohlbrenner, W. Antimicrob. Agents Chemother. (2002) [Pubmed]
  9. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. He, G., Massarella, J., Ward, P. Clinical pharmacokinetics. (1999) [Pubmed]
  10. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Ilyushina, N.A., Bovin, N.V., Webster, R.G., Govorkova, E.A. Antiviral Res. (2006) [Pubmed]
  11. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Li, W., Escarpe, P.A., Eisenberg, E.J., Cundy, K.C., Sweet, C., Jakeman, K.J., Merson, J., Lew, W., Williams, M., Zhang, L., Kim, C.U., Bischofberger, N., Chen, M.S., Mendel, D.B. Antimicrob. Agents Chemother. (1998) [Pubmed]
  12. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Eisenberg, E.J., Bidgood, A., Cundy, K.C. Antimicrob. Agents Chemother. (1997) [Pubmed]
  13. Oseltamivir. Bardsley-Elliot, A., Noble, S. Drugs (1999) [Pubmed]
  14. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. Kim, C.U., Lew, W., Williams, M.A., Wu, H., Zhang, L., Chen, X., Escarpe, P.A., Mendel, D.B., Laver, W.G., Stevens, R.C. J. Med. Chem. (1998) [Pubmed]
  15. Potential risks associated with the proposed widespread use of Tamiflu. Singer, A.C., Nunn, M.A., Gould, E.A., Johnson, A.C. Environ. Health Perspect. (2007) [Pubmed]
  16. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Hill, G., Cihlar, T., Oo, C., Ho, E.S., Prior, K., Wiltshire, H., Barrett, J., Liu, B., Ward, P. Drug Metab. Dispos. (2002) [Pubmed]
  17. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Boivin, G., Goyette, N. Antiviral Res. (2002) [Pubmed]
  18. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Ives, J.A., Carr, J.A., Mendel, D.B., Tai, C.Y., Lambkin, R., Kelly, L., Oxford, J.S., Hayden, F.G., Roberts, N.A. Antiviral Res. (2002) [Pubmed]
  19. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Mendel, D.B., Tai, C.Y., Escarpe, P.A., Li, W., Sidwell, R.W., Huffman, J.H., Sweet, C., Jakeman, K.J., Merson, J., Lacy, S.A., Lew, W., Williams, M.A., Zhang, L., Chen, M.S., Bischofberger, N., Kim, C.U. Antimicrob. Agents Chemother. (1998) [Pubmed]
  20. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Robson, R., Buttimore, A., Lynn, K., Brewster, M., Ward, P. Nephrol. Dial. Transplant. (2006) [Pubmed]
  21. High-performance liquid chromatographic determination of GS4071, a potent inhibitor of influenza neuraminidase, in plasma by precolumn fluorescence derivatization with naphthalenedialdehyde. Eisenberg, E.J., Cundy, K.C. J. Chromatogr. B Biomed. Sci. Appl. (1998) [Pubmed]
WikiGenes - Universities